Socioeconomic burden of AQP4-antibody seropositive NMOSD: a nationwide registry-based study

  • Published on 08/30/2024
  •  Reading time: 2 min.

Viktoria Papp1, Malthe Wandall-Holm2, Kristina Bacher Svendsen3, Jette Frederiksen4, Finn Sellebjerg4, Zsolt Illes1, Melinda Magyari2,4

1Department of Neurology, Odense University Hospital, Odense, Denmark
2Danish Multiple Sclerosis Registry, Department of Neurology, Copenhagen University Hospital – Rigshospitalet, Glostrup, Copenhagen, Denmark
3Neurology, Aarhus University Hospital, Aarhus C, Denmark
4Department of Neurology, Danish Multiple Sclerosis Center, Department of Neurology, Copenhagen University Hospital – Rigshospitalet, Glostrup, Copenhagen, Denmark

Correspondence to Dr Viktoria Papp; papp.vittoria@gmail.com

Abstract

Background AQP4-antibody seropositive (AQP4-Ab+) neuromyelitis optica spectrum disorder (NMOSD) may cause reduced work capability due to disability. Here, we evaluated the socioeconomic status of patients with AQP4-Ab+NMOSD in off-label therapy era compared with the general population.
Methods A longitudinal nationwide population-based study including all Danish patients with AQP4-Ab+NMOSD and matched controls from the general population. The cohort was...

ContentGeneMD

To continue reading this article in Full-Text...

* Access is totally free, without commitment or condition. Service exclusively reserved for healthcare professionals.

Peer-Reviewed Journals A-Z

Search | Advanced search

Get the latest news in Rare Diseases

Receive our newsletter to stay up to date with the latest news in Rare Diseases